FDA Approval Insights: Nirogacestat in Progressing Desmoid Tumors Requiring Systemic Treatment
Season 10, Episode 7, Jan 15, 07:00 PM
Dr Kasper discusses the FDA approval of nirogacestat for patients with progressing desmoid tumors; key efficacy, safety, and quality-of-life outcomes from the pivotal DeFi trial; and findings from an analysis investigating tumor volume and T2 hyperintensity changes with nirogacestat in patients enrolled in DeFi.